 |
市场调查报告书
商品编码
1801772
全球靶向蛋白质降解市场（按类型、适应症、剂型和最终用户划分）- 预测至 2035 年Targeted Protein Degradation Market by Type [PROTACs (Vepdegestrant, Bavdegalutamide), SERDs (Elacestrant), Molecular Glues (Mezigdomide), LDD, LYTAC/ATAC], Indication (Oncology, Inflammatory), Formulation (Oral), End User - Global Forecast to 2035 |
||||||
价格
全球标靶蛋白质降解市场预计将从 2025 年的 4.8 亿美元成长到 2035 年的 98.5 亿美元，2025 年至 2035 年的复合年增长率为 35.4%。
| 调查范围 | |
|---|---|
| 调查年份 | 2024-2035 |
| 基准年 | 2024 |
| 预测期 | 2025-2035 |
| 单元 | 10亿美元 |
| 部分 | 类型、治疗适应症、剂型、最终用户、地区 |
| 目标区域 | 北美、欧洲、亚太地区、拉丁美洲、中东和非洲 |
靶向蛋白质降解市场的扩张主要受到资本流入、与大型製药企业的合作以及多种适应症的扩展的推动，然而，异双功能CMC、扩大规模的复杂性以及知识产权纠纷预计会抑制市场的成长。
在治疗适应症领域中，预计肿瘤学领域将在 2024 年呈现最高的复合年增长率。
在所有治疗适应症领域中，肿瘤学领域预计将在标靶蛋白质降解市场中呈现最高的复合年增长率。这种快速增长的动力来自全球癌症发病率的上升，以及对曾经被认为无法治癒的致病蛋白质的治疗方法的迫切需求。包括PROTAC和分子胶降解剂在内的TPD技术透过降解而不是抑制关键致癌性蛋白质提供了一种突破性的方法，从而产生更完整和持久的治疗效果。多家生技和製药公司正在开发用于治疗癌症的TPD候选药物，包括摄护腺癌、乳癌、肺癌、血液癌和固体癌。 Arvinas、Kymera Therapeutics、Nurix Therapeutics和C4 Therapeutics等行业领导者正在开发针对关键癌症相关蛋白质（包括AR、ER、STAT3和BTK）的临床阶段降解剂。此外，与大型製药企业的伙伴关係以及监管机构日益增加的支持正在加快开发时间表。
由于精准医疗日益受到关注、癌症盛行率不断上升以及现有疗法的局限性，肿瘤学领域预计将主导靶向蛋白质降解市场。 TPD 设计、生物标记整合和联合治疗的持续创新预计将进一步推动成长，并巩固肿瘤学作为该市场最具活力和前景的应用领域的地位。
根据最终用户，居家照护环境部门在目标蛋白质降解市场中录得最高的复合年增长率。
2024年，居家照护照护领域成为标靶蛋白降解药物 (TPD) 市场成长最快的终端用户领域，这得益于对以患者为中心、便利且经济高效的治疗方案日益增长的需求。促成这一趋势的关键因素之一是口服TPD製剂的持续开发，这使得患者能够在舒适的家中管理癌症和自体免疫疾病等复杂疾病。与需要在诊所给药的生物製药不同，口服TPD无需频繁就医，从而实现了安全有效的治疗，并显着提高了患者的依从性和生活品质。远端患者监护和远距远端医疗平台等数位医疗技术的整合进一步推动了向居家护理的转变，这些技术使医生能够即时追踪治疗反应并管理副作用。医疗保健系统正在积极推广居家照护模式，以减轻医院负担并控制治疗成本。随着许多标靶蛋白降解药物进入后期临床开发并获得监管部门核准，居家照护的主导地位预计将进一步增强。由于其便利性、扩充性以及与现代医疗保健服务模式的一致性，居家照护环境在不断发展的治疗领域中代表了 TPD 治疗的重要且不断扩大的管道。
2025-2030年间，北美将占据全球标靶蛋白质降解市场的最大份额。
北美占据靶向蛋白降解市场的最大份额，这得益于其强大的生物技术创新基础、良好的监管环境和积极的投资活动。该地区拥有Arvinas、Kymera Therapeutics、Nurix Therapeutics和C4 Therapeutics等领先的标靶蛋白降解（TPD）公司，将尖端降解技术推进到临床开发阶段。此外，百时美施贵宝和辉瑞等大型製药企业也正在透过合作和内部研发积极拓展其标靶蛋白降解（TPD）产品线。该地区拥有成熟的医疗基础设施、顶尖学术研究机构的资源以及对新型治疗方法的早期应用。
本报告分析了全球靶向蛋白质降解市场，提供了关键驱动因素和限制因素、竞争格局和未来趋势的资讯。
目录
第一章 引言
第二章调查方法
第三章执行摘要
第四章 主要发现
- 标靶蛋白质降解市场概述
- 北美标靶蛋白质降解市场（按降解剂类型和国家划分）（2030 年）
- 标靶蛋白质降解市场：地理成长机会
- 标靶蛋白质降解市场：新兴市场与已开发市场
第五章市场概述
- 介绍
- 市场动态
- 驱动程式
- 抑制因素
- 机会
- 任务
- 技术分析
- 主要技术
- 互补技术
- 邻近技术
- 影响客户业务的趋势/中断
- 定价分析
- ELACESTRANT (ORSERDU) 的质性定价考量 (2024)
- 关于新型标靶蛋白质降解药物未来定价的定性考虑
- ELACESTRANT (ORSERDU) 的赎回方案
- 美国
- 欧洲
- 价值链分析
- 生态系分析
- 专利分析
- 管道分析
- 监管分析
- 区域监管机构、政府机构和其他组织
- 法规结构
- 大型会议和活动（2025-2026年）
- 波特五力分析
- 主要相关利益者和采购标准
- 投资金筹措场景
- 人工智慧/生成式人工智慧对标靶蛋白质降解市场的影响
- 2025年美国关税对标靶蛋白质降解市场的影响
- 介绍
- 主要关税税率
- 价格影响分析
- 对国家的影响
- 对终端产业的影响
6. 标靶蛋白质降解市场（依降解剂类型）
- 介绍
- 分子胶
- MEZIGDOMIDE（CC-92480）
- IBERDOMIDE（CC-220）
- SERD
- ELACESTRANT
- GIREDESTRANT（GDC9545）
- CAMIZESTRANT（AZD9833）
- PROTAC
- VEPDEGESTRANT（ARV-471）
- LUXDEGALUTAMIDE
- BGB-16673
- NX-5948
- KT-474
- LDD/BIDAC
- LYTAC/ATAC
- AUTAC/ATTEC
7. 标靶蛋白质降解市场（按治疗适应症）
- 介绍
- 癌症
- 发炎性疾病
- 其他疾病
8. 标靶蛋白质降解市场（按配方）
- 介绍
- 口服製剂
- 药片
- 胶囊
- 注射
9. 目标蛋白质降解市场（依最终用户）
- 介绍
- 医院和专科诊所
- 长期照护机构
- 居家照护环境
第十章 标靶蛋白质降解市场（按地区）
- 介绍
- 北美洲
- 北美宏观经济分析
- 美国
- 加拿大
- 欧洲
- 欧洲宏观经济分析
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 其他欧洲国家
- 亚太地区
- 亚太宏观经济分析
- 中国
- 日本
- 印度
- 韩国
- 澳洲
- 其他亚太地区
- 拉丁美洲
- 拉丁美洲宏观经济分析
- 巴西
- 墨西哥
- 其他拉丁美洲
- 中东和非洲
- 中东和非洲的宏观经济分析
- 海湾合作委员会国家
- 其他中东和非洲地区
第十一章竞争格局
- 介绍
- 主要参与企业的策略/优势
- 收益分析（2028-2030）
- 市场占有率分析（2030年）
- 公司估值及财务指标
- 品牌/产品比较
- 企业评估矩阵：主要企业（2024年）
- 公司评估矩阵：Start-Ups/中小企业（2024 年）
- 竞争场景
第十二章：公司简介
- 主要企业
- BRYSTOL-MYERS SQUIBB COMPANY
- THE MENARINI GROUP
- ARVINAS
- BEONE MEDICINES
- NURIX THERAPEUTICS, INC.
- KYMERA THERAPEUTICS, INC.
- C4 THERAPEUTICS, INC.
- ASTRAZENECA
- F. HOFFMANN-LA ROCHE LTD
- BAYER AG
- CAPTOR THERAPEUTICS
- RANOK THERAPEUTICS CO. LTD.
- PFIZER INC.
- NOVARTIS AG
- FOGHORN THERAPEUTICS
- 其他公司
- MONTE ROSA THERAPEUTICS
- BIOTHERYX, INC.
- CULLGEN
- NEOMORPH
- LYCIA THERAPEUTICS
- PHOTYS THERAPEUTICS
- PLEXIUM, INC.
- SEED THERAPEUTICS, INC.
- AVILAR THERAPEUTICS, INC.
- AUTOMERA
第十三章 附录
Product Code: PH 9483
The global targeted protein degradation market is projected to reach USD 9.85 billion by 2035 from an estimated USD 0.48 billion in 2025, at a CAGR of 35.4% from 2025 to 2035.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2024-2035 |
| Base Year | 2024 |
| Forecast Period | 2025-2035 |
| Units Considered | Value (USD billion) |
| Segments | By Type, Therapeutic Indication, Formulation, End User, and Region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
The expansion of the targeted protein degradation market has been predominantly fueled by Capital inflows & big-pharma tie-ups, and multi-indication expansion. However, CMC & scale-up complexity for heterobifunctional and IP disputes are expected to restrain market growth.
The oncology segment reported the highest CAGR in the therapeutic indications segment in 2024.
Based on therapeutic indications, the market is categorized into oncology, inflammatory diseases, and other therapeutic indications. Oncology is projected to exhibit the highest CAGR in the targeted protein degradation Market among all therapeutic indication segments. This rapid growth is driven by the increasing global burden of cancer and the urgent need for therapies that can target disease-causing proteins once considered undruggable. TPD technologies, including PROTACs and molecular glue degraders, offer a revolutionary approach by degrading, rather than inhibiting key oncogenic proteins, leading to more complete and durable therapeutic responses. Several biotech and pharmaceutical companies are advancing TPD candidates specifically for oncology indications, including prostate, breast, lung, hematologic, and solid tumors. Industry leaders, such as Arvinas, Kymera Therapeutics, Nurix Therapeutics, and C4 Therapeutics, are developing clinical-stage degraders targeting critical cancer-related proteins like AR, ER, STAT3, and BTK. Additionally, big pharma partnerships and increasing regulatory support are accelerating development timelines.
With a growing focus on precision medicine, rising cancer incidence, and limitations of existing therapies, the oncology segment is poised to dominate the targeted protein degradation market. Continued innovation in TPD design, biomarker integration, and combination therapies will further drive growth and solidify oncology's role as the most dynamic and promising application area in this market.
The homecare settings segment registered the highest CAGR in the targeted protein degradation market by end user.
The targeted protein degradation market is segmented by end users into hospitals & specialty clinics, long-term care facilities, and home care settings. In 2024, the home care settings segment emerged as the fastest-growing end-user segment in the targeted protein degraders (TPD) market, driven by the growing demand for patient-centric, convenient, and cost-effective treatment options. One of the key factors contributing to this trend is the increasing development of oral TPD formulations, which allow patients to manage complex conditions like cancer and autoimmune diseases from the comfort of their homes. Unlike traditional biologics requiring hospital administration, oral degraders enable safe, effective treatment without the need for frequent clinic visits, significantly improving patient compliance and quality of life. The shift toward home-based care is further supported by the integration of digital health technologies, including remote patient monitoring and telehealth platforms, which allow physicians to track treatment response and manage side effects in real time. Healthcare systems are actively encouraging homecare models to reduce hospital burden and control treatment costs. As more targeted protein degraders progress through late-stage clinical development and gain regulatory approval, the dominance of home care settings is expected to strengthen. With their convenience, scalability, and alignment with modern healthcare delivery models, home care environments represent a vital and expanding channel for TPD therapies in the evolving treatment landscape.
North America accounted for the largest share in the global targeted protein degradation market from 2025 to 2030.
North America accounted for the largest share in the targeted protein degradation market, driven by a strong foundation in biotechnology innovation, a favorable regulatory landscape, and significant investment activity. The region is home to several pioneering TPD companies, including Arvinas, Kymera Therapeutics, Nurix Therapeutics, and C4 Therapeutics, which are advancing cutting-edge degrader technologies into clinical development. In addition, major pharmaceutical firms such as Bristol Myers Squibb and Pfizer are actively expanding their TPD pipelines through collaborations and internal R&D. The region benefits from a mature healthcare infrastructure, access to top-tier academic research institutions, and early adoption of novel therapeutic modalities. The US Food and Drug Administration (FDA) has shown increasing recognition of TPD-based therapies, granting designations that facilitate faster development and approval. Furthermore, the growing emphasis on oral and home-based treatments aligns well with healthcare delivery models in North America.
These factors collectively position North America as a key driver of innovation, commercialization, and clinical advancement in the global TPD market, making it the fastest-growing regional segment.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side- 30%
- By Designation: Managers- 45%, CXO and Directors- 30%, and Executives- 25%
- By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%
Key Companies
Key players in the targeted protein degradation market include Bristol Myers Squibb (US), Arvinas (US), BeiGene (US), Nurix (US), Kymera (US), C4 Therapeutics (US), Stemline Therapeutics (US), AstraZeneca (UK), F. Hoffmann-La Roche Ltd (Switzerland), Bayer (Vividion) (Germany), Captor Therapeutics (Poland), Ranok Therapeutics (US), Pfizer (US), Novartis (Switzerland), and Foghorn Therapeutics (US).
Research Coverage
This research report categorizes the targeted protein degradation market, by type [molecular glue (mezigdomide, Iberdomide), SERDs (Elacestrant, Giredestrant, Camizestrant), PROTAC (Vepdegestrant, Bavdegalutamide, BGB-16673, NX-5948, KT-474), LDD/BiDAC, LYTAC/ATAC, Autophhagy-targeting chimeras] therapeutic indication (oncology, inflammatory diseases, and others), Formulation (oral formulationsand injections), end user (hospitals & speciality clinics, long-term care facility and home care settings) and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the targeted protein degradation market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the targeted protein degradation market.
Reasons to buy this report
The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall targeted protein degradation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing first-In-class approvals with priority/FT designations, expanding multi-indication use, increasing capital inflows and big-pharma collaborations, and technological advancements in degrader design and discovery) restraints (CMC and scale-up complexity for heterobifunctionals, off-target toxicity and cytokine storms in first-gen PROTACs, and IP disputes), opportunities (Growing adoption of CNS and immunology degraders in clinics, development of next-gen ligases with tissue-selective expression, and increasing NDA filing for innovative degraders), and challenges (Limited ligase expression and strict regulatory guidelines) influencing the growth of the market.
- Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the targeted protein degradation market
- Market Development: Comprehensive information about lucrative markets across varied regions
- Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the targeted protein degradation market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the targeted protein degradation market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Objectives of secondary research
- 2.1.1.2 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
- 2.1.2.2 Key objectives of primary research
- 2.1.1 SECONDARY DATA
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 GLOBAL MARKET SIZE ESTIMATION
- 2.2.1.1 Company revenue analysis (Bottom-up approach)
- 2.2.1.2 Revenue share analysis
- 2.2.1.3 MnM repository analysis
- 2.2.1.4 Primary interviews
- 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
- 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
- 2.2.1 GLOBAL MARKET SIZE ESTIMATION
- 2.3 GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
- 3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
- 3.1.1 BIOTECH STARTUPS AND INNOVATIVE COMPANIES
- 3.1.2 ESTABLISHED MARKET LEADERS
- 3.1.3 CDMOS AND CROS
4 PREMIUM INSIGHTS
- 4.1 TARGETED PROTEIN DEGRADERS MARKET OVERVIEW
- 4.2 NORTH AMERICA: TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE AND COUNTRY, 2030
- 4.3 TARGETED PROTEIN DEGRADERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 4.4 TARGETED PROTEIN DEGRADERS MARKET: EMERGING VS. DEVELOPED MARKETS
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing approvals and favorable regulatory environment
- 5.2.1.2 Multi-indication expansion
- 5.2.1.3 Capital inflows and big pharma tie-ups
- 5.2.1.4 Technological advancements in design and discovery
- 5.2.2 RESTRAINTS
- 5.2.2.1 Cost and scalability issues
- 5.2.2.2 Safety-related concerns
- 5.2.2.3 Intellectual property disputes
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Advancements in medicinal chemistry
- 5.2.3.2 Development of next-gen ligases with tissue-selective expressions
- 5.2.3.3 Increasing NDA filings for innovative degraders
- 5.2.4 CHALLENGES
- 5.2.4.1 Limited ligase expression in tissues
- 5.2.4.2 Strict regulatory guidelines
- 5.2.1 DRIVERS
- 5.3 TECHNOLOGY ANALYSIS
- 5.3.1 KEY TECHNOLOGIES
- 5.3.1.1 PROTACS (hetero-bifunctional)
- 5.3.1.2 Molecular glues/CELMODS
- 5.3.2 COMPLEMENTARY TECHNOLOGIES
- 5.3.2.1 Next-gen E3-ligase binder discovery
- 5.3.2.2 Nanoparticle/LNP delivery of degraders
- 5.3.3 ADJACENT TECHNOLOGIES
- 5.3.3.1 Antibody-drug conjugates (ADCs)
- 5.3.3.2 GENE editing/siRNA
- 5.3.1 KEY TECHNOLOGIES
- 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
- 5.5 PRICING ANALYSIS
- 5.5.1 QUALITATIVE PRICING INSIGHTS FOR ELACESTRANT (ORSERDU), 2024
- 5.5.2 QUALITATIVE PRICING INSIGHTS FOR UPCOMING NOVEL TARGETED PROTEIN DEGRADERS
- 5.6 REIMBURSEMENT SCENARIO FOR ELACESTRANT (ORSERDU)
- 5.6.1 US
- 5.6.2 EUROPE
- 5.7 VALUE CHAIN ANALYSIS
- 5.8 ECOSYSTEM ANALYSIS
- 5.9 PATENT ANALYSIS
- 5.10 PIPELINE ANALYSIS
- 5.11 REGULATORY ANALYSIS
- 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
- 5.11.2 REGULATORY FRAMEWORK
- 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
- 5.13 PORTER'S FIVE FORCES ANALYSIS
- 5.13.1 THREAT OF NEW ENTRANTS
- 5.13.2 THREAT OF SUBSTITUTES
- 5.13.3 BARGAINING POWER OF SUPPLIERS
- 5.13.4 BARGAINING POWER OF BUYERS
- 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.14.2 KEY BUYING CRITERIA
- 5.15 INVESTMENT AND FUNDING SCENARIO
- 5.16 IMPACT OF AI/GEN AI ON TARGETED PROTEIN DEGRADERS MARKET
- 5.17 IMPACT OF 2025 US TARIFFS ON TARGETED PROTEIN DEGRADERS MARKET
- 5.17.1 INTRODUCTION
- 5.17.2 KEY TARIFF RATES
- 5.17.3 PRICE IMPACT ANALYSIS
- 5.17.4 IMPACT ON COUNTRY/REGION
- 5.17.4.1 North America
- 5.17.4.1.1 US
- 5.17.4.2 Europe
- 5.17.4.3 Asia Pacific
- 5.17.4.1 North America
- 5.17.5 IMPACT ON END-USE INDUSTRIES
6 TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE
- 6.1 INTRODUCTION
- 6.2 MOLECULAR GLUE
- 6.2.1 MEZIGDOMIDE (CC-92480)
- 6.2.1.1 Stronger cereblon binding and deeper substrate degradation to spur growth
- 6.2.2 IBERDOMIDE (CC-220)
- 6.2.2.1 Rising incidence of autoimmune diseases and cancer to boost market
- 6.2.1 MEZIGDOMIDE (CC-92480)
- 6.3 SERDS
- 6.3.1 ELACESTRANT
- 6.3.1.1 Increasing approvals to contribute to growth
- 6.3.2 GIREDESTRANT (GDC9545)
- 6.3.2.1 Growing prevalence of breast cancer to drive market
- 6.3.3 CAMIZESTRANT (AZD9833)
- 6.3.3.1 High potency and strong receptor degradation to bolster growth
- 6.3.1 ELACESTRANT
- 6.4 PROTAC
- 6.4.1 VEPDEGESTRANT (ARV-471)
- 6.4.1.1 Reliable systemic exposure and enhanced tumor targeting to support growth
- 6.4.2 LUXDEGALUTAMIDE
- 6.4.2.1 Favorable safety profile and early signals of efficacy to stimulate growth
- 6.4.3 BGB-16673
- 6.4.3.1 Higher efficacy and preference for oral formulation to aid growth
- 6.4.4 NX-5948
- 6.4.4.1 Advancements in next-gen oral BTK degraders targeting refractory B-cell malignancies to drive market
- 6.4.5 KT-474
- 6.4.5.1 Rising importance in treating autoimmune and inflammatory diseases to aid growth
- 6.4.1 VEPDEGESTRANT (ARV-471)
- 6.5 LDD/BIDAC
- 6.5.1 INCREASING USE OF LDD IN TUMOR-SPECIFIC DEGRADATION, HEMATOLOGIC CANCERS, AND IMMUNE MODULATION TO FUEL MARKET
- 6.6 LYTAC/ATAC
- 6.6.1 GROWING FOCUS ON CANCER IMMUNOTHERAPY TO DRIVE MARKET
- 6.7 AUTAC/ATTEC
- 6.7.1 GROWING USE OF AUTAC IN TREATING METABOLIC DISEASES AND RARE LYSOSOMAL STORAGE CONDITIONS TO BOOST MARKET
7 TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION
- 7.1 INTRODUCTION
- 7.2 ONCOLOGY
- 7.2.1 HIGH PREVALENCE OF MALIGNANCIES AND UNMET NEED FOR DURABLE THERAPIES TO PROMOTE GROWTH
- 7.3 INFLAMMATORY DISEASES
- 7.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS TO AUGMENT GROWTH
- 7.4 OTHER DISEASES
8 TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION
- 8.1 INTRODUCTION
- 8.2 ORAL FORMULATIONS
- 8.2.1 TABLETS
- 8.2.1.1 Manufacturing scalability, stability, and patient convenience to aid growth
- 8.2.2 CAPSULES
- 8.2.2.1 Higher flexibility, faster development timelines, and enhanced bioavailability to foster growth
- 8.2.1 TABLETS
- 8.3 INJECTIONS
- 8.3.1 ESSENTIAL ROLE IN RAPID AND TARGETED DELIVERY OF SYSTEMIC TARGETED PROTEIN DEGRADERS TO BOOST MARKET
9 TARGETED PROTEIN DEGRADERS MARKET, BY END USER
- 9.1 INTRODUCTION
- 9.2 HOSPITALS & SPECIALTY CLINICS
- 9.2.1 ROBUST INFRASTRUCTURE AND MULTI-DISCIPLINARY CARE TEAMS TO EXPEDITE GROWTH
- 9.3 LONG-TERM CARE FACILITIES
- 9.3.1 INCREASING FOCUS ON QUALITY OF LIFE TO CONTRIBUTE TO GROWTH
- 9.4 HOME CARE SETTINGS
- 9.4.1 GROWING FOCUS ON CHRONIC DISEASE MANAGEMENT TO DRIVE MARKET
10 TARGETED PROTEIN DEGRADERS MARKET, BY REGION
- 10.1 INTRODUCTION
- 10.2 NORTH AMERICA
- 10.2.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA
- 10.2.2 US
- 10.2.2.1 Strong clinical pipeline and regulatory support to contribute to growth
- 10.2.3 CANADA
- 10.2.3.1 Favorable government initiatives to support growth
- 10.3 EUROPE
- 10.3.1 MACROECONOMIC ANALYSIS FOR EUROPE
- 10.3.2 GERMANY
- 10.3.2.1 Strong industry-academia partnership to foster growth
- 10.3.3 UK
- 10.3.3.1 Presence of leading academic institutions and translational research hubs to aid growth
- 10.3.4 FRANCE
- 10.3.4.1 Presence of leading biotechnology and diagnostic companies to spur growth
- 10.3.5 ITALY
- 10.3.5.1 Increasing innovations in PROTAC technology to promote growth
- 10.3.6 SPAIN
- 10.3.6.1 Robust academic network to contribute to growth
- 10.3.7 REST OF EUROPE
- 10.4 ASIA PACIFIC
- 10.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC
- 10.4.2 CHINA
- 10.4.2.1 Surge in clinical trial activities to spur growth
- 10.4.3 JAPAN
- 10.4.3.1 Large geriatric population to contribute to growth
- 10.4.4 INDIA
- 10.4.4.1 Expanding contract development and manufacturing organization infrastructure to fuel market
- 10.4.5 SOUTH KOREA
- 10.4.5.1 Rapidly expanding pharmaceutical manufacturing infrastructure to propel market
- 10.4.6 AUSTRALIA
- 10.4.6.1 Streamlined clinical trial environment to accelerate growth
- 10.4.7 REST OF ASIA PACIFIC
- 10.5 LATIN AMERICA
- 10.5.1 MACROECONOMIC ANALYSIS FOR LATIN AMERICA
- 10.5.2 BRAZIL
- 10.5.2.1 Regulatory evolution supporting trial acceleration to drive market
- 10.5.3 MEXICO
- 10.5.3.1 Rising demand for novel therapeutics for chronic disease treatment to support growth
- 10.5.4 REST OF LATIN AMERICA
- 10.6 MIDDLE EAST & AFRICA
- 10.6.1 MACROECONOMIC ANALYSIS FOR MIDDLE EAST & AFRICA
- 10.6.2 GCC COUNTRIES
- 10.6.2.1 Saudi Arabia
- 10.6.2.1.1 Growing focus on life sciences sector to boost market
- 10.6.2.2 UAE
- 10.6.2.2.1 Emerging biotechnology sector to intensify growth
- 10.6.2.3 REST OF GCC countries
- 10.6.2.1 Saudi Arabia
- 10.6.3 REST OF MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
- 11.1 INTRODUCTION
- 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TARGETED PROTEIN DEGRADERS MARKET
- 11.3 REVENUE ANALYSIS, 2028-2030
- 11.4 MARKET SHARE ANALYSIS, 2030
- 11.5 COMPANY VALUATION AND FINANCIAL METRICS
- 11.5.1 COMPANY VALUATION
- 11.5.2 FINANCIAL METRICS
- 11.6 BRAND/PRODUCT COMPARISON
- 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 11.7.1 STARS
- 11.7.2 EMERGING LEADERS
- 11.7.3 PERVASIVE PLAYERS
- 11.7.4 PARTICIPANTS
- 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 11.7.5.1 Company footprint
- 11.7.5.2 Region footprint
- 11.7.5.3 Degrader type footprint
- 11.7.5.4 Therapeutic indication footprint
- 11.7.5.5 Formulation footprint
- 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 11.8.1 PROGRESSIVE COMPANIES
- 11.8.2 RESPONSIVE COMPANIES
- 11.8.3 DYNAMIC COMPANIES
- 11.8.4 STARTING BLOCKS
- 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
- 11.8.5.1 Detailed list of key startups/SMEs
- 11.8.5.2 Competitive benchmarking of key startups/SMEs
- 11.9 COMPETITIVE SCENARIO
- 11.9.1 PRODUCT LAUNCHES AND APPROVALS
- 11.9.2 DEALS
- 11.9.3 EXPANSIONS
12 COMPANY PROFILES
- 12.1 KEY PLAYERS
- 12.1.1 BRYSTOL-MYERS SQUIBB COMPANY
- 12.1.1.1 Business overview
- 12.1.1.2 Products offered
- 12.1.1.3 Recent developments
- 12.1.1.3.1 Deals
- 12.1.1.3.2 Expansions
- 12.1.1.4 MnM view
- 12.1.1.4.1 Key strengths
- 12.1.1.4.2 Strategic choices
- 12.1.1.4.3 Weaknesses and competitive threats
- 12.1.2 THE MENARINI GROUP
- 12.1.2.1 Business overview
- 12.1.2.2 Products offered
- 12.1.2.3 Recent developments
- 12.1.2.3.1 Product launches and approvals
- 12.1.2.4 MnM view
- 12.1.2.4.1 Key strengths
- 12.1.2.4.2 Strategic choices
- 12.1.2.4.3 Weaknesses and competitive threats
- 12.1.3 ARVINAS
- 12.1.3.1 Business overview
- 12.1.3.2 Products offered
- 12.1.3.3 Recent developments
- 12.1.3.3.1 Deals
- 12.1.3.4 MnM view
- 12.1.3.4.1 Key strengths
- 12.1.3.4.2 Strategic choices
- 12.1.3.4.3 Weaknesses and competitive threats
- 12.1.4 BEONE MEDICINES
- 12.1.4.1 Business overview
- 12.1.4.2 Products offered
- 12.1.4.3 Recent developments
- 12.1.4.3.1 Deals
- 12.1.5 NURIX THERAPEUTICS, INC.
- 12.1.5.1 Business overview
- 12.1.5.2 Products offered
- 12.1.5.3 Recent developments
- 12.1.5.3.1 Deals
- 12.1.6 KYMERA THERAPEUTICS, INC.
- 12.1.6.1 Business overview
- 12.1.6.2 Products offered
- 12.1.6.3 Recent developments
- 12.1.6.3.1 Deals
- 12.1.7 C4 THERAPEUTICS, INC.
- 12.1.7.1 Business overview
- 12.1.7.2 Products offered
- 12.1.7.3 Recent developments
- 12.1.7.3.1 Deals
- 12.1.8 ASTRAZENECA
- 12.1.8.1 Business overview
- 12.1.8.2 Products offered
- 12.1.8.3 Recent developments
- 12.1.8.3.1 Deals
- 12.1.8.3.2 Expansions
- 12.1.9 F. HOFFMANN-LA ROCHE LTD
- 12.1.9.1 Business overview
- 12.1.9.2 Products offered
- 12.1.9.3 Recent developments
- 12.1.9.3.1 Deals
- 12.1.10 BAYER AG
- 12.1.10.1 Business overview
- 12.1.10.2 Products offered
- 12.1.10.3 Recent developments
- 12.1.10.3.1 Deals
- 12.1.11 CAPTOR THERAPEUTICS
- 12.1.11.1 Business overview
- 12.1.11.2 Products offered
- 12.1.11.3 Recent developments
- 12.1.11.3.1 Deals
- 12.1.12 RANOK THERAPEUTICS CO. LTD.
- 12.1.12.1 Business overview
- 12.1.12.2 Products offered
- 12.1.12.3 Recent developments
- 12.1.12.3.1 Product launches and approvals
- 12.1.13 PFIZER INC.
- 12.1.13.1 Business overview
- 12.1.13.2 Products offered
- 12.1.13.3 Recent developments
- 12.1.13.3.1 Product launches and approvals
- 12.1.14 NOVARTIS AG
- 12.1.14.1 Business overview
- 12.1.14.2 Products offered
- 12.1.14.3 Recent developments
- 12.1.14.3.1 Deals
- 12.1.15 FOGHORN THERAPEUTICS
- 12.1.15.1 Business overview
- 12.1.15.2 Products offered
- 12.1.15.3 Recent developments
- 12.1.15.3.1 Deals
- 12.1.1 BRYSTOL-MYERS SQUIBB COMPANY
- 12.2 OTHER PLAYERS
- 12.2.1 MONTE ROSA THERAPEUTICS
- 12.2.2 BIOTHERYX, INC.
- 12.2.3 CULLGEN
- 12.2.4 NEOMORPH
- 12.2.5 LYCIA THERAPEUTICS
- 12.2.6 PHOTYS THERAPEUTICS
- 12.2.7 PLEXIUM, INC.
- 12.2.8 SEED THERAPEUTICS, INC.
- 12.2.9 AVILAR THERAPEUTICS, INC.
- 12.2.10 AUTOMERA
13 APPENDIX
- 13.1 DISCUSSION GUIDE
- 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 13.3 CUSTOMIZATION OPTIONS
- 13.4 RELATED REPORTS
- 13.5 AUTHOR DETAILS
List of Tables
- TABLE 1 NOVEL TARGETED PROTEIN DEGRADERS MARKET: INCLUSIONS AND EXCLUSIONS
- TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
- TABLE 3 NOVEL TARGETED PROTEIN DEGRADERS MARKET: RISK ANALYSIS
- TABLE 4 NOVEL TARGETED PROTEIN DEGRADERS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
- TABLE 5 KEY STRATEGIC PARTNERSHIPS IN NOVEL TARGETED PROTEINS MARKET
- TABLE 6 REIMBURSEMENT SCENARIO IN EUROPEAN COUNTRIES
- TABLE 7 NOVEL TARGETED PROTEIN DEGRADERS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
- TABLE 8 NUMBER OF PATENTS FILED (APPLIED/GRANTED) IN NOVEL TARGETED PROTEIN DEGRADERS MARKET, 2014-2024
- TABLE 9 NOVEL TARGETED PROTEIN DEGRADERS MARKET: LIST OF PATENTS, 2022-2024
- TABLE 10 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PRODUCTS IN CLINICAL PIPELINE, 2025-2028
- TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 15 NOVEL TARGETED PROTEIN DEGRADERS MARKET: REGULATORY SCENARIO
- TABLE 16 NOVEL TARGETED PROTEIN DEGRADERS MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
- TABLE 17 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PORTER'S FIVE FORCES ANALYSIS
- TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DEGRADER TYPE (%)
- TABLE 19 KEY BUYING CRITERIA, BY END USER
- TABLE 20 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 21 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 22 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY REGION, 2023-2035 (USD MILLION)
- TABLE 23 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 24 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 25 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY REGION, 2023-2035 (USD MILLION)
- TABLE 26 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 27 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY REGION, 2023-2035 (USD MILLION)
- TABLE 28 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 29 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY REGION, 2023-2035 (USD MILLION)
- TABLE 30 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 31 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 32 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 33 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 34 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY REGION, 2023-2035 (USD MILLION)
- TABLE 35 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MEZIGDOMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 36 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY REGION, 2023-2035 (USD MILLION)
- TABLE 37 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 38 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 39 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 40 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023-2032 (USD MILLION)
- TABLE 41 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY REGION, 2023-2035 (USD MILLION)
- TABLE 42 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR IBERDOMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 43 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 44 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY REGION, 2023-2035 (USD MILLION)
- TABLE 45 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 46 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 47 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 48 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 49 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY REGION, 2023-2035 (USD MILLION)
- TABLE 50 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 51 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY REGION, 2023-2035(USD MILLION)
- TABLE 52 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY COUNTRY, 2023-2035(USD MILLION)
- TABLE 53 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY COUNTRY, 2023-2035(USD MILLION)
- TABLE 54 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY COUNTRY, 2023-2035(USD MILLION)
- TABLE 55 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY COUNTRY, 2023-2035(USD MILLION)
- TABLE 56 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY REGION, 2023-2035(USD MILLION)
- TABLE 57 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ELACESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 58 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY REGION, 2023-2035 (USD MILLION)
- TABLE 59 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 60 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 61 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 62 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 63 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY REGION, 2023-2035 (USD MILLION)
- TABLE 64 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR GIREDESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 65 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY REGION, 2023-2035 (USD MILLION)
- TABLE 66 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET CAMIZESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 67 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 68 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 69 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 70 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY REGION, 2023-2035 (USD MILLION)
- TABLE 71 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAMIZESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 72 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 73 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY REGION, 2023-2035 (USD MILLION)
- TABLE 74 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 75 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 76 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 77 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 78 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY REGION, 2023-2035 (USD MILLION)
- TABLE 79 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 80 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY REGION, 2023-2035 (USD MILLION)
- TABLE 81 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 82 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 83 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 84 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 85 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY REGION, 2023-2035 (USD MILLION)
- TABLE 86 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR VEPDEGESTRANT, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 87 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY REGION, 2023-2035 (USD MILLION)
- TABLE 88 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 89 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 90 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 91 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 92 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY REGION, 2023-2035 (USD MILLION)
- TABLE 93 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LUXDEGALUTAMIDE, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 94 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY REGION, 2023-2035 (USD MILLION)
- TABLE 95 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 96 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 97 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 98 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 99 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY REGION, 2023-2035 (USD MILLION)
- TABLE 100 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR BGB-16673, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 101 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY REGION, 2023-2035 (USD MILLION)
- TABLE 102 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 103 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 104 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 105 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR NX-5948, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 106 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT-474, BY REGION, 2023-2035 (USD MILLION)
- TABLE 107 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT-474, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 108 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT-474, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 109 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR KT-474, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 110 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY REGION, 2023-2035 (USD MILLION)
- TABLE 111 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 112 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 113 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 114 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 115 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY REGION, 2023-2035 (USD MILLION)
- TABLE 116 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LDD/BIDAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 117 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LYTAC/ATAC, BY REGION, 2023-2035 (USD MILLION)
- TABLE 118 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LYTAC/ATAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 119 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LYTAC/ATAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 120 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LYTAC/ATAC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 121 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC/ATTEC, BY REGION, 2023-2035 (USD MILLION)
- TABLE 122 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC/ ATTEC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 123 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC /ATTEC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 124 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR AUTAC /ATTEC, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 125 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 126 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY REGION, 2023-2035 (USD MILLION)
- TABLE 127 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 128 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 129 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 130 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 131 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY REGION, 2023-2035 (USD MILLION)
- TABLE 132 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 133 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2023-2035 (USD MILLION)
- TABLE 134 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 135 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 136 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 137 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR OTHER DISEASES, BY REGION, 2023-2035 (USD MILLION)
- TABLE 138 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 139 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 140 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 141 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 142 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 143 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY REGION, 2023-2035 (USD MILLION)
- TABLE 144 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 145 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 146 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 147 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 148 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY REGION, 2023-2035 (USD MILLION)
- TABLE 149 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 150 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY REGION, 2023-2035 (USD MILLION)
- TABLE 151 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 152 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 153 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 154 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 155 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY REGION, 2023-2035 (USD MILLION)
- TABLE 156 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR TABLETS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 157 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY REGION, 2023-2035 (USD MILLION)
- TABLE 158 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 159 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 160 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 161 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 162 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY REGION, 2023-2035 (USD MILLION)
- TABLE 163 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR CAPSULES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 164 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS, BY REGION, 2023-2035 (USD MILLION)
- TABLE 165 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 166 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 167 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR INJECTIONS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 168 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 169 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2023-2035 (USD MILLION)
- TABLE 170 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 171 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 172 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 173 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 174 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2023-2035 (USD MILLION)
- TABLE 175 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 176 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2035 (USD MILLION)
- TABLE 177 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 178 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 179 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 180 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 181 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2035 (USD MILLION)
- TABLE 182 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 183 NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY REGION, 2023-2035 (USD MILLION)
- TABLE 184 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 185 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2028 (USD MILLION)
- TABLE 186 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 187 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 188 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY REGION, 2023-2035 (USD MILLION)
- TABLE 189 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 190 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY REGION, 2023-2035 (USD MILLION)
- TABLE 191 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
- TABLE 192 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 193 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 194 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 195 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 196 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 197 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 198 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 199 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 200 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 201 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 202 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 203 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 204 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 205 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 206 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 207 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 208 US: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 209 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 210 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 211 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 212 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 213 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 214 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 215 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 216 CANADA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 217 EUROPE: KEY MACROECONOMIC INDICATORS
- TABLE 218 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 219 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 220 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 221 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 222 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 223 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 224 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 225 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 226 EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 227 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 228 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 229 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 230 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 231 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 232 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 233 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 234 GERMANY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 235 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 236 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 237 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 238 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 239 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 240 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 241 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 242 UK: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 243 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 244 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 245 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 246 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 247 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 248 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 249 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 250 FRANCE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 251 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 252 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 253 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 254 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 255 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 256 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 257 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 258 ITALY: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 259 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 260 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 261 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 262 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 263 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 264 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 265 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 266 SPAIN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 267 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 268 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 269 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 270 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 271 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 272 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 273 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 274 REST OF EUROPE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 275 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
- TABLE 276 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 277 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 278 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 279 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 280 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 281 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 282 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 283 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 284 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 285 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 286 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 287 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 288 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 289 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 290 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 291 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 292 CHINA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 293 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 294 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 295 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 296 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 297 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 298 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 299 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 300 JAPAN: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 301 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 302 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 303 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 304 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 305 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 306 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 307 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 308 INDIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 309 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 310 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 311 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 312 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 313 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 314 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 315 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 316 SOUTH KOREA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 317 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 318 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 319 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 320 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 321 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 322 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 323 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 324 AUSTRALIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 325 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 326 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 327 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 328 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 329 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 330 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 331 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 332 REST OF ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 333 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
- TABLE 334 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 335 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 336 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 337 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 338 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 339 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 340 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 341 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 342 LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 343 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 344 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 345 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 346 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 347 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 348 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 349 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 350 BRAZIL: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 351 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 352 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 353 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 354 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 355 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 356 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 357 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 358 MEXICO: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 359 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 360 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 361 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 362 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 363 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 364 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 365 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 366 REST OF LATIN AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 367 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
- TABLE 368 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY REGION, 2023-2035 (USD MILLION)
- TABLE 369 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 370 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 371 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 372 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 373 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 374 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 375 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 376 MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 377 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY COUNTRY, 2023-2035 (USD MILLION)
- TABLE 378 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 379 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 380 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 381 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 382 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 383 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 384 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 385 GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 386 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 387 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 388 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 389 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 390 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 391 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 392 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 393 SAUDI ARABIA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 394 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 395 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 396 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 397 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 398 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 399 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 400 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 401 UAE: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 402 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 403 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 404 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 405 REST OF GCC: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 406 REST OF GCC: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 407 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 408 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 409 REST OF GCC COUNTRIES: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 410 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2023-2035 (USD MILLION)
- TABLE 411 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR MOLECULAR GLUE, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 412 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR SERDS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 413 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR PROTAC, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 414 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2023-2035 (USD MILLION)
- TABLE 415 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2023-2035 (USD MILLION)
- TABLE 416 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET FOR ORAL FORMULATIONS, BY TYPE, 2023-2035 (USD MILLION)
- TABLE 417 REST OF MIDDLE EAST & AFRICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2023-2035 (USD MILLION)
- TABLE 418 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN NOVEL TARGETED PROTEIN DEGRADERS MARKET, 2023-2025
- TABLE 419 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DEGREE OF COMPETITION
- TABLE 420 NOVEL TARGETED PROTEIN DEGRADERS MARKET: REGION FOOTPRINT
- TABLE 421 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DEGRADER TYPE FOOTPRINT
- TABLE 422 NOVEL TARGETED PROTEIN DEGRADERS MARKET: THERAPEUTIC INDICATION FOOTPRINT
- TABLE 423 NOVEL TARGETED PROTEIN DEGRADERS MARKET: FORMULATION FOOTPRINT
- TABLE 424 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
- TABLE 425 NOVEL TARGETED PROTEIN DEGRADERS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2024
- TABLE 426 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-AUGUST 2025
- TABLE 427 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DEALS, JANUARY 2022-AUGUST 2025
- TABLE 428 NOVEL TARGETED PROTEIN DEGRADERS MARKET: EXPANSIONS, JANUARY 2022- AUGUST 2025
- TABLE 429 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
- TABLE 430 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
- TABLE 431 BRISTOL MYERS SQUIBB COMPANY: DEALS, JANUARY 2022-JULY 2025
- TABLE 432 BRISTOL-MYERS SQUIBB COMPANY: EXPANSIONS, JANUARY 2022-JULY 2025
- TABLE 433 THE MENARINI GROUP: COMPANY OVERVIEW
- TABLE 434 THE MENARINI GROUP: PRODUCTS OFFERED
- TABLE 435 THE MENARINI GROUP: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
- TABLE 436 ARVINAS: COMPANY OVERVIEW
- TABLE 437 ARVINAS: PRODUCTS OFFERED
- TABLE 438 ARVINAS: DEALS, JANUARY 2022-JULY 2025
- TABLE 439 BEONE MEDICINES: COMPANY OVERVIEW
- TABLE 440 BEONE MEDICINES: PRODUCTS OFFERED
- TABLE 441 BEONE MEDICINES: DEALS, JANUARY 2022-JULY 2025
- TABLE 442 NURIX THERAPEUTICS, INC.: COMPANY OVERVIEW
- TABLE 443 NURIX THERAPEUTICS, INC.: PRODUCTS OFFERED
- TABLE 444 NURIX THERAPEUTICS, INC.: DEALS, JANUARY 2022-JULY 2025
- TABLE 445 KYMERA THERAPEUTICS, INC.: COMPANY OVERVIEW
- TABLE 446 KYMERA THERAPEUTICS, INC.: PRODUCTS OFFERED
- TABLE 447 KYMERA THERAPEUTICS, INC.: DEALS, JANUARY 2022-JULY 2025
- TABLE 448 C4 THERAPEUTICS, INC.: COMPANY OVERVIEW
- TABLE 449 C4 THERAPEUTICS, INC.: PRODUCTS OFFERED
- TABLE 450 C4 THERAPEUTICS, INC.: DEALS, JANUARY 2022-JULY 2025
- TABLE 451 ASTRAZENECA: COMPANY OVERVIEW
- TABLE 452 ASTRAZENECA: PRODUCTS OFFERED
- TABLE 453 ASTRAZENECA: DEALS, JANUARY 2022-JULY 2025
- TABLE 454 ASTRAZENECA: EXPANSIONS, JANUARY 2022-JULY 2025
- TABLE 455 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
- TABLE 456 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
- TABLE 457 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022-JULY 2025
- TABLE 458 BAYER AG: COMPANY OVERVIEW
- TABLE 459 BAYER AG: PRODUCTS OFFERED
- TABLE 460 BAYER AG: DEALS, JANUARY 2022-JULY 2025
- TABLE 461 CAPTOR THERAPEUTICS: COMPANY OVERVIEW
- TABLE 462 CAPTOR THERAPEUTICS: PRODUCTS OFFERED
- TABLE 463 CAPTOR THERAPEUTICS: DEALS, JANUARY 2022-JULY 2025
- TABLE 464 RANOK THERAPEUTICS CO. LTD.: COMPANY OVERVIEW
- TABLE 465 RANOK THERAPEUTICS CO. LTD.: PRODUCTS OFFERED
- TABLE 466 RANOK THERAPEUTICS CO. LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
- TABLE 467 PFIZER INC.: COMPANY OVERVIEW
- TABLE 468 PFIZER INC.: PRODUCTS OFFERED
- TABLE 469 PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
- TABLE 470 NOVARTIS AG: COMPANY OVERVIEW
- TABLE 471 NOVARTIS AG: PRODUCTS OFFERED
- TABLE 472 NOVARTIS AG: DEALS, JANUARY 2022-JULY 2025
- TABLE 473 FOGHORN THERAPEUTICS: COMPANY OVERVIEW
- TABLE 474 FOGHORN THERAPEUTICS: PRODUCTS OFFERED
- TABLE 475 FOGHORN THERAPEUTICS: DEALS, JANUARY 2022-JULY 2025
- TABLE 476 MONTE ROSA THERAPEUTICS: COMPANY OVERVIEW
- TABLE 477 BIOTHERYX, INC.: COMPANY OVERVIEW
- TABLE 478 CULLGEN: COMPANY OVERVIEW
- TABLE 479 NEOMORPH: COMPANY OVERVIEW
- TABLE 480 LYCIA THERAPEUTICS: COMPANY OVERVIEW
- TABLE 481 PHOTYS THERAPEUTICS: COMPANY OVERVIEW
- TABLE 482 PLEXIUM, INC.: COMPANY OVERVIEW
- TABLE 483 SEED THERAPEUTICS, INC.: COMPANY OVERVIEW
- TABLE 484 AVILAR THERAPEUTICS, INC.: COMPANY OVERVIEW
- TABLE 485 AUTOMERA: COMPANY OVERVIEW
List of Figures
- FIGURE 1 NOVEL TARGETED PROTEIN DEGRADERS MARKET SEGMENTATION AND REGIONAL SCOPE
- FIGURE 2 NOVEL TARGETED PROTEIN DEGRADERS MARKET: YEARS CONSIDERED
- FIGURE 3 NOVEL TARGETED PROTEIN DEGRADERS MARKET: RESEARCH DESIGN
- FIGURE 4 NOVEL TARGETED PROTEIN DEGRADERS MARKET: KEY DATA FROM SECONDARY SOURCES
- FIGURE 5 NOVEL TARGETED PROTEIN DEGRADERS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
- FIGURE 6 NOVEL TARGETED PROTEIN DEGRADERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
- FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2030
- FIGURE 8 REVENUE SHARE ANALYSIS OF MENARINI GROUP, 2024
- FIGURE 9 NOVEL TARGETED PROTEIN DEGRADERS MARKET SIZE VALIDATION FROM PRIMARY SOURCES
- FIGURE 10 NOVEL TARGETED PROTEIN DEGRADERS MARKET: TOP-DOWN APPROACH
- FIGURE 11 NOVEL TARGETED PROTEIN DEGRADERS MARKET: CAGR PROJECTIONS
- FIGURE 12 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DATA TRIANGULATION
- FIGURE 13 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE, 2030 VS. 2035 (USD MILLION)
- FIGURE 14 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION, 2030 VS. 2035 (USD MILLION)
- FIGURE 15 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION, 2030 VS. 2035 (USD MILLION)
- FIGURE 16 NOVEL TARGETED PROTEIN DEGRADERS MARKET, BY END USER, 2030 VS. 2035 (USD MILLION)
- FIGURE 17 GEOGRAPHICAL SNAPSHOT OF NOVEL TARGETED PROTEIN DEGRADERS MARKET
- FIGURE 18 INCREASING RESEARCH INVESTMENTS AND RISING DEMAND FOR TARGETED TREATMENT TO DRIVE MARKET
- FIGURE 19 SERDS SEGMENT AND US TO LEAD NORTH AMERICAN MARKET IN 2030
- FIGURE 20 AUSTRALIA TO HAVE HIGHEST GROWTH DURING FORECAST PERIOD
- FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
- FIGURE 22 NOVEL TARGETED PROTEIN DEGRADERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 23 NEW REVENUE POCKETS FOR PLAYERS IN NOVEL TARGETED PROTEIN DEGRADERS MARKET
- FIGURE 24 NOVEL TARGETED PROTEIN DEGRADERS MARKET: VALUE CHAIN ANALYSIS
- FIGURE 25 NOVEL TARGETED PROTEIN DEGRADERS MARKET: ECOSYSTEM ANALYSIS
- FIGURE 26 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PATENT ANALYSIS, JANUARY 2014-DECEMBER 2024
- FIGURE 27 NOVEL TARGETED PROTEIN DEGRADERS MARKET: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DEGRADER TYPE
- FIGURE 29 KEY BUYING CRITERIA, BY END USER
- FIGURE 30 NOVEL TARGETED PROTEIN DEGRADERS MARKET: INVESTMENT AND FUNDING SCENARIO, 2021-2024
- FIGURE 31 NOVEL TARGETED PROTEIN DEGRADERS MARKET: IMPACT OF AI/GEN AI
- FIGURE 32 NORTH AMERICA: NOVEL TARGETED PROTEIN DEGRADERS MARKET SNAPSHOT
- FIGURE 33 ASIA PACIFIC: NOVEL TARGETED PROTEIN DEGRADERS MARKET SNAPSHOT
- FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS, 2028-2030 (USD MILLION)
- FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NOVEL TARGETED PROTEIN DEGRADERS MARKET, 2030
- FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
- FIGURE 37 EV/EBITDA OF KEY VENDORS
- FIGURE 38 NOVEL TARGETED PROTEIN DEGRADERS MARKET: BRAND/PRODUCT COMPARISON
- FIGURE 39 NOVEL TARGETED PROTEIN DEGRADERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
- FIGURE 40 NOVEL TARGETED PROTEIN DEGRADERS MARKET: COMPANY FOOTPRINT
- FIGURE 41 NOVEL TARGETED PROTEIN DEGRADERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
- FIGURE 42 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2024)
- FIGURE 43 THE MENARINI GROUP: COMPANY SNAPSHOT (2024)
- FIGURE 44 ARVINAS: COMPANY SNAPSHOT (2024)
- FIGURE 45 BEONE MEDICINES: COMPANY SNAPSHOT (2024)
- FIGURE 46 NURIX THERAPEUTICS, INC.: COMPANY SNAPSHOT (2024)
- FIGURE 47 KYMERA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2024)
- FIGURE 48 C4 THERAPEUTICS, INC.: COMPANY SNAPSHOT (2024)
- FIGURE 49 ASTRAZENECA: COMPANY SNAPSHOT (2024)
- FIGURE 50 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
- FIGURE 51 BAYER AG: COMPANY SNAPSHOT (2024)
- FIGURE 52 PFIZER INC.: COMPANY SNAPSHOT (2024)
- FIGURE 53 NOVARTIS AG: COMPANY SNAPSHOT (2024)
- FIGURE 54 FORGHORN THERAPEUTICS: COMPANY SNAPSHOT (2024)
